



## **InterGenetics Builds DNA Analysis and Genotyping Laboratory**

### **Laboratory Essential to Commercialization of Nation's First Genetic-based Breast Cancer Risk Predictive Test applicable to all Women— *OncoVue*®**

**For Immediate Release:**  
September 7, 2005

**For More Information Contact:**  
Jane Braden 405 818-1905

OKLAHOMA CITY—InterGenetics Incorporated, a genetic cancer risk-intervention company, announced today that construction is complete on its DNA Analysis and Genotyping Laboratory. This 11,000 square-foot laboratory and headquarters will become the national hub for processing *OncoVue*®, the next-generation genetic breast cancer risk test. *OncoVue* will be the first genetic-based breast cancer risk predictive test that can determine the lifetime and age-specific risk of developing breast cancer applicable for all women.

“Completion of the InterGenetics DNA Analysis and Genotyping Laboratory is a significant milestone for InterGenetics and the development of *OncoVue*, paving the way for final transition from the research phase to the commercial introduction of this test,” said Dr. Craig Shimasaki, InterGenetics’ president and CEO. “InterGenetics has completed the majority of its financing this summer, raising over \$8 million dollars that will be used to expand operations and launch *OncoVue* this year.”

InterGenetics now work on final preparations for the process of earning CLIA certification. The *Clinical Laboratory Improvement Amendment (CLIA)* certification is administered under the *Center for Medical and Medicaid Services*, the agency that regulates the quality of the nation’s laboratory processing. InterGenetics anticipate receiving CLIA certification in October 2005, allowing the company to commence offering *OncoVue* through selected breast care centers across the country.

“We have a growing network of quality breast care centers in place around the country, ready to offer *OncoVue* to their patients once they are comprehensively trained and we receive final CLIA certification,” noted Dr. Shimasaki. “We continue to add to that list with centers that have protocols and programs to help the high-risk patients for breast cancer.”

InterGenetics projects 15,000 tests to be processed in the new laboratory in the first 12 months of operation and anticipates doubling its current staff to accommodate the market demand.

The OncoVue test is easily performed. A woman first answers a simple medical history questionnaire, then swishes a harmless mouthwash and deposits the fluid in a tube. The mouthwash solution and the medical history information collected at the breast care centers will be sent to the InterGenetics DNA Analysis and Genotyping Laboratory, where the DNA will be extracted from the solution and analyzed using InterGenetics' proprietary algorithms and technology. The results of the lab analysis will be converted into a series of risk scores that represent a woman's risk of developing breast cancer at various stages of her life. That score will be sent to the breast care center, which will have protocols in place to inform its patient of her risk level and translate that information into the appropriate action.

These centers have the ability to offer high-risk women alternative programs that could include preventative medications to reduce the occurrence of the disease, or to utilize more comprehensive screening tools to catch breast cancer at its earliest stages where long term survival is the greatest.

"InterGenetics' scientists have discovered that using algorithms that analyze combinations of multiple genes is a better way to determine an individual's personal breast cancer risk than previous assessment tools," continued Shimasaki. "Combinations of genes along with personal history measures determine a more complete genetic picture of breast cancer susceptibility by looking at interactions of genes that impact risk rather than the limited picture any single gene can offer."

The laboratory construction project relocated InterGenetics' facility to 655 Research Parkway in the Presbyterian Health Foundation Research Park in the growing biotech corridor of Oklahoma City. The added space also houses InterGenetics' research and development laboratories, administration, market relations, and medical and genetic testing support services.

#### About InterGenetics

InterGenetics, a genetics-based cancer-risk testing and cancer treatment company is emerging as an innovator in the frontier of genetic medicine. The company's lead product, the OncoVue® Breast Cancer Risk Test, uses proprietary gene combinations and DNA assessment technology developed by InterGenetics' scientists to quickly and accurately identify women who are at high risk of developing breast cancer, potentially many years in advance of their diagnosis.

InterGenetics has a promising research pipeline of predictive tests for other cancers such as ovarian, colon, prostate, and pancreatic cancer. The company's core research has future application in also predicting heart disease, diabetes and in enhancing the effectiveness of drug therapies and preventative medicine in these fields.

[www.intergenetics.com](http://www.intergenetics.com)